期刊
VACCINE
卷 34, 期 24, 页码 2663-2670出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.04.034
关键词
Human metapneumovirus; Paramyxovirus; Vaccine; T cell response; Respiratory infections
资金
- NIH [AI085062, AI040079, AI042286, HL054977]
- VA Merit Award [BX001444]
- Vanderbilt Ingram Cancer Center [P30 CA68485]
- Vanderbilt Digestive Disease Research Center [DK058404]
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8(+) T cell (T-CD8) epitopes, with M39-47 (M39) immunodominant. Tetramer staining detected M39-specific T-CD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that T-CD8 from HLA-A*0201 positive humans recognize M39 by IFN gamma ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据